Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

e NDA submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... Seroquel) is an important drug for the treatment ... in 2000, quetiapine was listed in the Catalogue ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 7, 2011 Akorn, Inc. (NASDAQ: AKRX ... 2011, to discuss third quarter 2011 results followed by a ... day before the market opens. Subject: , Akorn, Inc. ... 2011, at 10:00 a.m. Eastern TimeDomestic Callers: , (888) ...
... PARSIPPANY, N.J., Oct. 7, 2011 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated ... Drug Administration (FDA) seeking approval to market Morphine Sulfate ... mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and ...
Cached Medicine Technology:Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
(Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... On ... College (EMCC), one of the 10 regionally accredited Maricopa Community Colleges , ... to network with college students pursuing employment information and opportunities. , The Expo has ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... How Eating Disorders Affect Loved Ones At ... The Remuda Cornerstone Bookstore on May 2, PHOENIX, ... the nation,s leading and largest inpatient,treatment center for women and ... with the authors of the new book "Distorted -,How a ...
... on human immune cell may be key to stopping infection ... at suppressing HIV target proteins lying on the virus itself, ... immune cells might work even better. , That,s because human ... the virus would have much less chance of mutating around ...
... More than 6,000 internists (doctors of internal medicine), ... meet in Washington, D.C., for Internal Medicine 2008, ... of Physicians (ACP), from May 15 - 17 ... Internal Medicine 2008 is the largest continuing medical ...
... 29 /PRNewswire-FirstCall/ - Traxxec,Ltd, the UK subsidiary of ... today announces that, in line with the licence ... at the Interpack conference,and trade show in Dusseldorf, ... will be present at this,meeting giving the Traxxec ...
... third of Downs syndrome children who wear bifocal lenses to ... for two years, according to new research from Cardiff University. ... Syndrome Research Unit has studied the reasons for poor focussing ... of the children in the study who adopted bifocals to ...
... April 29 Gunther von Hagens, BODY WORLDS, the,traveling ... this week. Though it will not be known if ... at BODY WORLDS in Los Angeles, or if,the honor ... in Milwaukee, or,Baltimore, or Manchester, England, the number is ...
Cached Medicine News:Health News:Authors Of New Critically Acclaimed Book 'Distorted' Share Their Journey From an Eating Disorder at a Book Signing Event in Wickenburg 2Health News:Researchers Tackle HIV From a New Angle 2Health News:Researchers Tackle HIV From a New Angle 3Health News:ACP hosts largest medical education meeting for general and subspecialty internists 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 3Health News:A life 'lens' ordinary 2Health News:Gunther Von Hagens' BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone 2Health News:Gunther Von Hagens' BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone 3
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
Uvex Patriot Frame...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
Medicine Products: